Baloxavir marboxil as a therapeutic option to treat influenza in Poland.
Bibliographic record
Abstract
Searching for new drugs for the treatment of influenza is important due to the epidemiological significance of this disease entity, affecting a significant percentage of people around the world. Preventive vaccinations, which significantly improve the overall epidemiological situation in the analysed population, cannot completely solve the problem, which results from numerous pharmacological and social conditions. Among drugs available in Poland now are amantadine, rimantadine, oseltamivir and zanamivir, but their effectiveness is not satisfactory, and from the other hand can be hard to use among patients not prepared to use inhalators. Baloxavir marboxil is one of the newest influenza A and B medications approved in Japan (2018), the United States of America (2019) and Australia, Canada and Switzerland (2020). It works by inhibiting a specific viral cap-dependent endonuclease and blocking RNA transcription in the infected cell. A single administration of 40 or 80 mg of the drug up to 48 hours after the onset of symptoms results in a reduction in viral load and the duration of fever and other symptoms of the disease, usually without serious side effects, like diarrhoea, nausea and headache, and can be used in children after dose adjustment according to their weight. Clinical trials show that reducing the duration of symptoms is not significantly different from other drugs. But oral administration in one dose and a 48 hour treatment window, longer than other drugs in this sentencing, may be taken as the most important advantages. The disadvantages are the possibility of resistance occurring after just one administration, the high cost, and accessibility problems. Baloxavir marboxil is an effective drug against the influenza virus and is used both in the treatment and prevention of adults and children over 12 years of age. The factors limiting the applicability are the price higher than other therapies and the lack of registration in the European Union, which, however, does not exclude the possibility of use.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".